<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7367788\results\search\country\results.xml">
  <result pre="has emerged in late December 2019 in Wuhan city of" exact="China" post="and spread rapidly to other parts of the world."/>
  <result pre="inducing metabolic and epigenetic changes. Clinical trials are underway in" exact="Australia" post="and Netherlands for determining the efficacy of BCG vaccines"/>
  <result pre="and epigenetic changes. Clinical trials are underway in Australia and" exact="Netherlands" post="for determining the efficacy of BCG vaccines in healthcare"/>
  <result pre="and inhibits viral RNA synthesis Approved to treat influenza in" exact="Japan" post="Ribavirin (antiviral, guanine nucleotide analog) Phase 1/2 Target RdRp"/>
  <result pre="4 Inhibits fusion between viral and cellular membrane Approved in" exact="Russia" post="and China for the prophylaxis and treatment of influenza"/>
  <result pre="fusion between viral and cellular membrane Approved in Russia and" exact="China" post="for the prophylaxis and treatment of influenza A, B,"/>
  <result pre="action and thereby inhibits viral entry to cells Approved in" exact="Japan" post="for chronic pancreatitis and drug-induced lung injury Clevudine (synthetic"/>
  <result pre="The published report of treatment of first COVID-19 patients in" exact="the USA" post="and remdesivirâ€™s use in a 53-patient case series have"/>
  <result pre="emergency use authorization (EUA) for treating hospitalized COVID-19 patients by" exact="the US" post="Food and Drug Administration (FDA). Promising signals from various"/>
  <result pre="thus ceasing viral replication [27]. It has been approved in" exact="Japan" post="and China for the treatment of novel influenza virus"/>
  <result pre="viral replication [27]. It has been approved in Japan and" exact="China" post="for the treatment of novel influenza virus infections, and"/>
  <result pre="treatment of novel influenza virus infections, and in March 2020," exact="China" post="has approved its use for COVID-19 patients. A study"/>
  <result pre="E6 cells [19]. A study conducted on COVID-19 patients in" exact="China" post="has stated the more potent antiviral action (shorter time"/>
  <result pre="interferon-alpha [28]. Furthermore, a prospective, multicenter, open-label, randomized trial in" exact="China" post="comparing favipiravir with arbidol has shown better recovery profile"/>
  <result pre="group [40]. But, a prospective study of 30 patients in" exact="China" post="stated that there was no difference in clinical outcomes"/>
  <result pre="Recently, the results of a most awaited trial conducted in" exact="the USA" post="on 96,032 COVID-19 patients using HCQ and CQ with"/>
  <result pre="along with standard treatment in a clinical trial conducted in" exact="China" post="(ChiCTR2000029757) [51]. These data support the utility of convalescent"/>
  <result pre="a recent open-label phase 2 trial (NCT04346355) conducted in the" exact="Italy" post="was stopped early because of lack of benefit of"/>
  <result pre="injury and ARDS [64â€&quot;66]. Recently, a pilot study conducted in" exact="China" post="on seven COVID-19 patients, who had received intravenous infusions"/>
  <result pre="patient outcomes on further use. Also, on April 5, 2020," exact="the US" post="FDA has approved mesenchymal stem cell (MSC) treatments for"/>
  <result pre="antiviral effect to prevent SARS-CoV-2 infection [70]. Medical institutions in" exact="China" post="have published many TCM prescriptions, and guideline in China"/>
  <result pre="in China have published many TCM prescriptions, and guideline in" exact="China" post="(The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan, 6th"/>
  <result pre="[69]. On February 17, The National Health Commission (NHC) of" exact="China" post="has reported the beneficial effect of TCM in around"/>
  <result pre="To date, more than 50 clinical trials have registered in" exact="China" post="for the evaluation of TCM in COVID-19. Luo, et"/>
  <result pre="subjects performed by any of the authors. References References 1.ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRNiuPZhanFMaXWangDXuWWuGGaoGFTanWcollab:" exact="China" post="Novel Coronavirus Investigating and Research TeamA novel coronavirus from"/>
 </snippets>
</snippetsTree>
